Taat Lifestyle & Wellness - CEO, Setti Coscarella
CEO, Setti Coscarella
Source: Tabacco Reporter
  • TAAT (TAAT) receives its first national mainstream media coverage in the US with an article published by Forbes profiling the company
  • The article details the value proposition of TAAT™ as an alternative to tobacco cigarettes due to its inherently non-addictive properties
  • TAAT™ Chief Executive Officer Setti Coscarella shares his professional background and journey to his current role at the company
  • The company will be hosting a live Q&A session with Mr. Coscarella on a Facebook Live stream at 9:15 am PST / 12:15 pm EST on Thursday, February 4
  • TAAT (TAAT) is up 6.54 per cent, trading at C$3.42 at 4 pm EST

TAAT (TAAT) receives its first national mainstream media coverage in the United States.

In addition to sharing his professional background with Forbes contributor Amanda Siebert, TAAT™ Chief Executive Officer Setti Coscarella, discusses TAAT’s partnership with packaged goods sales agency CROSSMARK.

Mr. Coscarella also details the value proposition of TAAT™ as an alternative to tobacco cigarettes and explains the strategy behind positioning TAAT™ as a tobacco category product to appeal to legal-aged smokers who could prefer a familiar product format. 

In regards to the article, Setti Coscarella commented, “Obtaining coverage of TAAT™ in a national mainstream news outlet such as Forbes is a tremendous milestone because it demonstrates positive reception and validation of TAAT™ as a company that is gaining momentum in the  $814 billion tobacco industry.

On behalf of the entire team, I can say we are very thankful for Amanda Siebert’s interest in the product and the company, and we hope this coverage helps to bring additional eyeballs of legal-aged smokers to TAAT™.”

The company will be hosting a live Q&A session with Mr. Coscarella on a Facebook Live stream at 9:15 am PST / 12:15 pm EST on Thursday, February 4, 2021. 

TAAT (TAAT) is up 6.54 per cent, trading at C$3.42 at 4 pm EST.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.